Cargando…
Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys
Duchenne muscular dystrophy (DMD) is caused by loss of dystrophin in muscle, and while all patients share the primary gene and biochemical defect, there is considerable patient–patient variability in clinical symptoms. We sought to develop multivariate models of serum protein biomarkers that explain...
Autores principales: | Dang, Utkarsh J, Ziemba, Michael, Clemens, Paula R, Hathout, Yetrib, Conklin, Laurie S, Hoffman, Eric P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471506/ https://www.ncbi.nlm.nih.gov/pubmed/32592467 http://dx.doi.org/10.1093/hmg/ddaa132 |
Ejemplares similares
-
Comparison of Serum Pharmacodynamic Biomarkers in Prednisone-Versus Deflazacort-Treated Duchenne Muscular Dystrophy Boys
por: Tawalbeh, Shefa, et al.
Publicado: (2020) -
Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy
por: Ogundele, Michael, et al.
Publicado: (2021) -
Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2019) -
Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy
por: Fang, Yuan, et al.
Publicado: (2023) -
Clinical utility of serum biomarkers in Duchenne muscular dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2016)